Objective:

To evaluate the efficacy and safety of OCS-01, a topical eye drop for diabetic macular edema (DME), as an alternative to intravitreal injections, addressing a significant unmet need in DME treatment.

Key Findings:

• Statistically significant improvement in best-corrected visual acuity (BCVA) with OCS-01 compared to placebo at week 6 (7.2 letters vs 3.1 letters, P=0.007), indicating a meaningful clinical benefit.
• Sustained BCVA gains through week 12 (7.6 letters vs 3.7 letters, P=0.016), reinforcing the treatment's efficacy.
• Significant reductions in central subfield thickness (CST) at week 6 (69.1 µm) and week 12 (45 µm), highlighting anatomical improvements.
• 27.4% of OCS-01 patients achieved a ≥15-letter BCVA gain by week 12 compared to 7.5% in the placebo group (P=0.009), demonstrating a substantial treatment effect.
• Both treatment-naïve and previously treated patients showed consistent visual and anatomical improvements, suggesting broad applicability.

Interpretation:

OCS-01 demonstrates potential as a first topical treatment for DME, offering significant visual and anatomical benefits while reducing the need for invasive procedures, leveraging its unique delivery mechanism.

Limitations:

• Increased intraocular pressure (IOP) was noted in the OCS-01 group, with some cases requiring medication, which may impact long-term treatment decisions.
• One treatment-emergent adverse effect led to discontinuation of the study drug, indicating the need for careful monitoring.

Conclusion:

OCS-01 shows promise as an effective topical treatment for DME, with ongoing trials expected to provide further data that could significantly impact patient care.